Relation of von Willebrand factor to occurrence of Q waves and thrombolytic treatment in acute myocardial infarction

American Journal of Cardiology

Volumn 81, Issue 4, 1998, Pages 497-500

  Tousoulis, Dimitris ^a   Davies, Graham ^b   Tentolouris, Costas ^b   Bosinakou, Eirini ^b   Toutouzas, Pavlos ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL ARTICLE; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; Q WAVE; VON WILLEBRAND DISEASE;

ADULT; AGED; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOGEN; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 0032520052     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00953-3     Document Type: Article

References (19)

1. 1. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988;77: 1213-1220.
2. 2. Aguirre FV, Younis LT, Chaitman BR, Ross AM, McMahon RP, Kern MJ, Berger PB, Sopko G, Rogers WJ, Shaw L, Knatterud G, Braunwald E, for the TIMI II Investigators. Early and 1-year clinical outcome of patients' evolving non-Q-wave versus Q-wave myocardial infarction after thrombolysis. Results from the TIMI II study. Circulation 1995;91:2541-2548.
3. 3. Paramo JA, Colucci M, Collen D, Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985;291:573-574.
4. 4. Stel HV, Sakariassen KS, de Groot PG, van Mourik JA, Sixma JJ. von Willebrand factor in the vessel wall mediates platelet adherence. Blood 1985;65: 85-90.
5. 5. Sane DC, Stump DC, Topol EJ, Sigmon KN, Kereiakes DJ, George BS, Mantell SJ, Macy E, Collen D, Califf RM. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemost 1991; 65:275-279.
6. 6. Andreotti F, Roncaglioni MC, Hackett DR, Khan MI, Regan T, Haider AW, Davies GJ, Kluft C, Maseri A. Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von-Willebrand factor in acute myocardial infarction. J Am Coll Cardiol 1990;16:1553-1560.
7. 7. Sakamoto T, Yasue H, Ogawa H, Misumi I, Masuda T. Association of patency of the infarct-related coronary artery with plasma levels of plasminogen activator inhibitor activity in acute myocardial infarction. Am J Cardiol 1992;70:271-276.
8. 8. Margulis T, David M, Maor N, Soff GA, Grenadier E, Palant A, Aghai E. The von-Willebrand factor in myocardial infarction and unstable angina: a kinetic study. Thromb Haemost 1986;55:366-368.
9. 9. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329: 673-82.
10. 10. Ingerslev J. A sensitive ELISA for von-Willenbrand factor (vWt: Ag). Scand J Clin Lab Invest 1987;47:143-149.
11. 11. Tousoulis D, Bosinakou E, Tentolouris C, Apostolopoulos T, Copshari C, Kyriakides M, Toutouzas P. t-plasminogen activator and von Willebrand factor in patients with unstable angina. Int J Cardiol 1996;54:89-92.
12. 12. Soskin P, Wiesel ML, Mossard JM, Abrogast R, Najib K, Grunebaum L, Sacrez A, Cazenave JP. Von Willebrand factor in coronary disease. Arch Mal Coeur Vaiss 1994;87:85-93.
13. 13. Gibson RS, Beller GA, Gheorghiade M, Nycaard TW, Watson DD, Huey BL, Sayre SL, Kaiser DL. The prevalence and clinical significance of residual myocardial ischemia 2 weeks after uncomplicated non-Q wave myocardial infarction. Circulation 1986;73:1186-1198.
14. 14. Maise AS, Ahnve S, Gilpin E, Henning H, Golberger AL, Collins D, LeWinter M, Ross J. Prognosis after extension of myocardial infarct: the role of Q wave or non-Q wave infarction. Circulation 1985;71:211-217.
15. 15. Vermylen JG, Chamone DAF. The role of the fibrinolytic system in thromboembolism. Prog Cardiovasc Dis 1979;21:255-266.
16. 16. Klein LW, Helfant RH. The Q-wave and non-Q wave myocardial infarction: differences and similarities. Prog Cardiovasc Dis 1986;29:205-220.
17. 17. Uren NG, Crake T, Lefroy DC, DeSilva R, Davies GJ, Maseri A. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med 1994;331:222-7.
18. 18. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990;82(suppl II):II-38-II-46.
19. 19. Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, Nasmith J, Fung AY, Boudreault JR, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ, on Behalf of the Investigators. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian Lamifiban Study. Circulation 1996;94:899-905.